Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis. Cui M, Fu J, Li Q. BMC Cancer 2024;24:1293.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Cui M, Fu J, Li Q. Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis. BMC Cancer 2024;24:1293.
PMID: 39425072